Financial Hearings webcast presentation at 15.00 EEST
https://ir.financialhearings.com/nanoform-q2-2023
Invitation to Nanoform’s Q2 2023 Interim Report
Press release Nanoform Finland Plc August 10, 2023 11:00 a.m.…
Characterization of the Flux Performance of Nanoformed and Untreated Crystalline Piroxicam Solid Suspensions, and the Relative Contributions of the Particle Drifting Effect to In Vitro Flux.
Presented at the 2023 Controlled Release Society Annual Meeting by…
Nanoforming – the Patient- and Planet-Centric Approach From Increasing Bioavailability to Enabling Sustained Drug Delivery.
Nanoforming has emerged as a patient- and planet-centric approach to…
Nanoform and Celanese Demonstrate Enhanced Drug Delivery through the Power of Smaller Implants
Press release Nanoform Finland Plc June 15, 2023 08:10 a.m.…
Budesonide Nanocrystal Manufacturing Using Controlled Expansion of Supercritical Solutions (CESS®)
Senior Formulation Scientist, Barry Derham, and VP of BD in…